Form 4: Akoya Biosciences CFO John Frederick Ek Reports Acquisition of Shares and Stock Options

CFO John Frederick Ek reports acquisition of 35,000 shares of common stock and 70,000 employee stock options in Akoya Biosciences.

Summary

• John Frederick Ek, CFO of Akoya Biosciences, reported changes in beneficial ownership of securities.
• On February 22, 2024, Ek acquired 35,000 shares of common stock and 70,000 employee stock options.
• The restricted stock units vest in four equal annual installments starting March 1, 2025.
• The options vest with 25% on February 22, 2025, and the remainder in 36 equal monthly installments beginning March 22, 2025.
• Following the transaction, Ek directly owns 195,000 shares of common stock and indirectly owns 20,000 shares through the Ek Trust Dated November 20, 2020.
• Ek also directly owns 70,000 employee stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard SEC filing reflecting changes in beneficial ownership. The acquisition of shares and options by the CFO could be seen as a mildly positive signal, but it's not a major event.

Positives

• The acquisition of shares and stock options by the CFO could be interpreted as a positive sign of confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure related to executive compensation and ownership changes, common in the biotechnology industry.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates